US Patent Issued to Janssen Pharmaceutica on July 28 for "FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma" (Pennsylvania Inventors)

ALEXANDRIA, Va., July 28 -- United States Patent no. 12,691,112, issued on July 28, was assigned to Janssen Pharmaceutica NV (Beerse, Belgium).

"FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma" was invented by Anjali Narayan Avadhani (Springhouse, Pa.), Anne Elizabeth O'Hagan (Springhouse, Pa.) and Ademi Elena Santiago-Walker (Springhouse, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described here are methods of treating urothelial carcinoma in a patient comprising evaluating a biological sample from the patient for the presence of at least two fibroblast growth factor receptor (FGFR) genetic alterations and treating the patient with an FGFR inhibitor. Also described herein a...